Primary Outcomes:

Primary Outcome 1 - Measure: Phase 1b: Percentage of Participants with Dose-Limiting Toxicity (DLT)

Primary Outcome 1 - Time Frame: Up to 8 weeks

Primary Outcome 2 - Measure: Phase 2: Overall Response Rate (ORR) (Partial Response [PR] or Better) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator Assessment

Primary Outcome 2 - Time Frame: Up to 2 years

Primary Outcome 3 - Measure: Phase 2: Number of Participants with Adverse Event (AEs)

Primary Outcome 3 - Time Frame: Up to 2 years

Condition:

• Urothelial Carcinoma

Eligibility

Criteria:
Inclusion Criteria:

- Histologic demonstration of transitional cell carcinoma of the urothelium. Variant
urothelial carcinoma histologies such as glandular or squamous differentiation, or
evolution to more aggressive phenotypes such as sarcomatoid or micropapillary change
are acceptable

- Metastatic or locally advanced urothelial cancer

- Must have measurable disease by radiological imaging according to the Response
Evaluation Criteria in Solid Tumors (RECIST, version 1.1) at baseline

- Prior systemic therapy for metastatic urothelial cancer: (a) For Phase 1b erdafitinib
+ cetrelimab cohort: Any number of lines of prior therapy; (b) For Phase 1b
erdafitinib + cetrelimab + platinum chemotherapy cohort: No prior systemic therapy for
metastatic disease; and renal function for participants must have a creatinine
clearance (CrCl) greater than (>) 50 milliliter per minute (mL/min) as calculated by
Cockcroft Gault and (c) Phase 2: No prior systemic therapy for metastatic disease and
cisplatin-ineligible based on: ECOG PS 0-1 and at least one of the following criteria:
Renal function defined as creatinine clearance (CrCl) ˂60 mL/min as calculated by
Cockcroft‑Gault; Grade 2 or higher peripheral neuropathy per NCI-CTCAE version 5.0;
Grade 2 or higher hearing loss per NCI-CTCAE version 5.0 OR ECOG PS 2

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) grade of: (a) Phase
1b erdafitinib + cetrelimab cohort: ECOG 0-2; (b) Phase 1b erdafitinib + cetrelimab +
platinum chemotherapy cohort: ECOG 0-1 for cisplatin and 0-2 for carboplatin (c) Phase
2: ECOG 0-2

Exclusion Criteria:

- Treatment with any other investigational agent or participation in another clinical
study with therapeutic intent within 30 days prior to Cycle 1 Day 1. For Phase 1b,
participants who have received the following prior antitumor therapy: received
nitrosoureas and mitomycin C within 6 weeks

- Phase 1b erdafitinib + cetrelimab cohort: Chemotherapy within 3 weeks of Cycle 1 Day
1; Phase 1b erdafitinib + cetrelimab + platinum chemotherapy cohort and Phase 2: Prior
neoadjuvant/adjuvant chemotherapy is allowed if the last dose was given >12 months
prior to recurrent disease progression and did not result in drug-related toxicity
leading to treatment discontinuation

- Prior anti-programmed death receptor-1 (PD-1), anti-programmed death ligand-1 (PD-L1),
or anti-programmed death ligand-2 (PD-L2) therapy. Prior neoadjuvant/adjuvant
checkpoint inhibitor therapy is allowed if the last dose was given more than (>)12
months prior to recurrent disease progression and did not result in drug-related
toxicity leading to treatment discontinuation. PD-1 for non-muscle invasive bladder
cancer is also allowed

- Active malignancies requiring concurrent therapy other than urothelial cancer

- Symptomatic central nervous system metastases
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No